News

Video

Prostate Cancer Imaging: PSMA Agents and Radiotracer Options

Author(s):

David Albala, MD

Insight into advancements in prostate cancer imaging using PSMA agents like gallium and F-18, their unique characteristics, and the considerations in choosing the right radiotracer for accurate detection.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
      Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      Alicia Morgans, MD, MPH, on physician awareness of PSA doubling time in prostate cancer
      Channing J. Paller, MD, on communicating about natural products with patients with prostate cancer
      Channing J. Paller, MD, on communicating about natural products with patients with prostate cancer
      Vanita Gaglani, RPT, answers a question during a video interview
      Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
      Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes
      Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      Managing post-prostatectomy incontinence in patients with comorbidities
      Expert on challenges of clinical trials of natural products in prostate cancer
      Expert on challenges of clinical trials of natural products in prostate cancer
      Matthew Cooperberg, MD, reacts to 2025 ACS prostate cancer data
      Matthew Cooperberg, MD, reacts to 2025 ACS prostate cancer data
      Channing J. Paller, MD, answers a question during a Zoom video interview
      Channing J. Paller, MD, on vitamin C and prostate cancer
      Vanita Gaglani, RPT, answers a question during a video interview
      Physical therapist discusses her work in men undergoing prostatectomy
      Related Content
      Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
      February 19th 2025

      WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

      Benjamin P. Saylor
      Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | © Dr_Microbe - stock.adobe.com
      February 14th 2025

      Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

      Benjamin P. Saylor
      "Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      February 13th 2025

      Darolutamide is safe, efficacious in mHSPC regardless of patient age

      Benjamin P. Saylor
      "Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
      February 13th 2025

      Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

      Benjamin P. Saylor
      In both racial cohorts, median MFS was not reached in the darolutamide group.
      © 2025 MJH Life Sciences

      All rights reserved.